The effects of immunoliposomes targeting tumor-produced murine IL30, in a fully immunocompetent host, were tested by applying the conditions and schedule used for the treatment of PC xenografts (Supplementary Fig. 3). The gene discussed is IL27; the disease is neoplasm.